A tuberculosis vaccine administered during the previous 15 years is correlated with significantly enhanced COVID-19 outcomes, particularly in young adults, according to a new study.

The analysis, published in the journal Vaccines, found that BCG regimes are correlated with better COVID-19 outcomes, both in reducing disease rates and death rates , especially for people aged 24 or younger who had received the vaccination in the previous 15 decades.

There was no effect among older adults that had received the BCG vaccine, the researchers said.

Most nations have ceased inoculating their whole population, but some still use BCG extensively, they stated.

"A growing number of clinical trials for testing the efficacy of BCG vaccination have been pioneered," Rappoport said.

The researchers examined data from 55 countries with populations of more than three million individuals, which include some 63 percent of the planet's population.

Since the pandemic attained different nations at different dates, they steered nations by the first date at which the nation reached a passing rate of 0.5 deaths per million or higher.

The investigators controlled for 23 variables including demographic, economical, pandemic-restriction-related, and country health-based.

BCG vaccine management was shown to be continuously associated with COVID-19 results across the 55 states, '' they said.

To determine whether other vaccines also affected COVID-19 results, the team ran the same analysis for the measles and rubella vaccines and found that those did not have a significant association with COVID-19 outcomes.

Other epidemiological studies have shown the impact of the BCG vaccine past tuberculosis, however, scientists do not yet understand why the vaccine has such an effect.